Haleos Labs Ltd. · NSE:HALEOSLABS
Haleos Labs — SMS Lifesciences India — Q4 FY25 Earnings Presentation
26 slides from Haleos Labs's earnings presentation, Jul 14, 2025
Slide 1: Investor Presentation Q4-FY25 stock exchange cover letter
July 14, 2025 To BSE Limited, National Stock Exchange of India Limited, Listing Department, P J Towers, Listing Department, “Exchange Plaza”, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai - 400 051. Scrip Code: 540679 Trading Symbol: SMSLIFE Through: BSE Listing Center Thr
Slide 2: SMS Lifesciences India Limited Investor Presentation Q4 & FY25
SMS LIFESCIENCES INDIA LIMITED Abouton Industrial Standards this Itemplate Related N V E S Party T O R PTransactions RESENTATION – Q4 & FY 25 JULY 2025
Slide 3: About the Company
About the Company SMS Lifesciences is a global player in Pharmaceutical APIs/Intermediates manufacturing having strong research and manufacturing team supported by state of the art facilities accredited by USFDA, Japan PMDA, WHO GMP apart from other global regulatory authorities. The Company is oper
Slide 4: Journey so far
Journey so far... 2006 Incorporation The Company was officially incorporated 2016 Acquisition Company was acquired by SMS Pharma asa wholly owned subsidiary. 2017 Demerged 2 manufacturing facility were vested with Company vide NCLT demerger order dated May 15, 2017 2018 Acquired Mahi Drugs Acquired
Slide 5: Successful USFDA Audit Milestones
SUCCESSFUL USFDA AUDIT MILESTONES SUCCESSFUL USFDA AUDIT MILESTONES 2018 2022 Jan 2025 May 2025 Unit 1 of the Company located at Unit 1, Kazipalli with Manufacturing plant of Mahi Drugs Manufacturing plant at Kazipalli with one observation no observations (subsidiary) located at Vizag, with no Kazip
Slide 6: Business Update
BUSINESS UPDATE 6 LifeSciences Stable Project API Commercialization New Projects Revenues Execution Additions Start Contract Consistent income Successful Integration of S+ USEDA filings in manufacturing in SMS Life from intermediate APIs each in FY26 in Mahi Drugs Projects in SMS Ranitidine and proj
Slide 7: Capex Update
CAPEX UPDATE API Line Expansion Completion of a new API line expansion & will be operational from Q3FY26 S| sms LifeSciences New API Line Addition Addition of a new APT line in Mahi drugs by FY27
Slide 8: Regulatory Milestones
REGULATORY MILESTONES Upcoming ANVISA Inspection Scheduled ANVISA (Brazil) inspection in SMS Life (Unit 1) in Sep 2025 USFDA Inspection in Mahi Drugs Successful inspection by USFDA in January 2025 USFDA Inspection in SMS Life (Unit 1) Successful inspection by USFDA in May 2025 sm LifeSciences
Slide 9: Key Strategic Focus
Key Strategic Focus Carve out a strong presence in complex, niche APIs with focus on global leadership in multiple products Since demerger, capex of ₹ 145 crores to augment the next leg of growth. Global presence, Strong domain expertise, cost leadership, long standing relationship, economic of scal
Slide 10: Q4 & FY25 Performance
S| sms LifeSciences Q4 & FY25 PERFORMANCE
Slide 11: Performance Highlights (Standalone)
Performance Highlights (Standalone) ₹ in lakhs Particulars Q4F25 Q4F24 YoY Q3F25 QoQ FY25 FY24 YoY Revenue from Operations 8,542.78 8,637.37 -1.10% 8,287.65 3.08% 33,337.10 30,000.16 11.12% Cost of goods sold 5,890.91 6,144.35 -4.12% 5,471.97 7.66% 22,466.68 21,269.51 5.63% Gross profit 2,651.87 2,4
Slide 12: Performance Overview (Standalone)
Performance Overview (Standalone) Key financial metrics and year-over-year as well as quarter-over-quarter comparisons fro Q4FY25 & FY 25
Slide 13: Performance Highlights (Consolidated)
Performance Highlights (Consolidated) ₹ in lakhs Particulars Q4F25 Q4F24 YoY Q3F25 QoQ FY25 FY24 YoY Revenue from Operations 8,911.24 8,999.15 -0.98% 8,460.10 5.33% 34,472.35 30,595.84 12.67% Cost of goods sold 5,631.73 6,011.35 -6.32% 5,317.14 5.92% 21,961.05 20,879.26 5.18% Gross profit 3,279.51 2
Slide 14: Performance Overview (Consolidated)
Performance Overview (Consolidated) Key financial metrics and year-over-year as well as quarter-over-quarter comparisons fro Q4FY25 & FY 25
Slide 15: Dividend, Name Change and Director Reappointment
S| sms LifeSciences @ Dividend Declaration The Board announced a 21.50 dividend per equity share for FY 2024-25, subject to approval of shareholders. Name Change Proposal The Board approval for changing the narne of the Company to "HALEOS LABS LIMITED‘, subject to necessary approvals. Key updates re
Slide 16: Geographical Break-up
Geographical Break-up Company majorly exported to China, Indonesia, USA, Malaysia, Singapore, Spain, Brazil.
Slide 17: Historical Performance (Standalone)
Historical Performance (Standalone) ₹ in lakhs Profit before Tax Revenue ₹ Cash profit EPS ₹
Slide 18: Historical Performance (Consolidated)
Historical Performance (Consolidated) ₹ in lakhs Profit before Tax Revenue ₹ Cash profit EPS ₹
Slide 19: Factory – Unit 1 (Aerial View)
Factory – Unit 1 (Arial View) Built-up Area: 13619.87 Sq.M Green Belt Area: 15,248 Sq.M Plant Area: 47,581.62 Sq.M
Slide 20: Research & Development
Research & Development DSIR approved facility for Research & Company has spent ₹630 lakhs in the year 70 member highly skilled team along with scientists, Development located at Sanath Nagar, 2024-25 (i.e. 2% of the turnover) driving innovation across key focus areas Hyderabad During the last year,
Slide 21: Mahi Drugs Pvt. Ltd. (Subsidiary)
Mahi Drugs Pvt. Ltd. (Subsidiary) Established in the year Located in J.N Pharma World class 2 API lines & Can handle batch Storage facilities for Successfully 2012 and was acquired City, Parawada, Infrastructure and 4 Intermediate sizes ranging CRT (20-25 °C), inspected by by Company as Wholly- Anak
Slide 22: Supported by Comprehensive Chemicals and Process Capabilities
Supported by Comprehensive Chemicals and Process Capabilities… Can maintain minimum temperature of -70oC and maximum temperature of 220o C, at pressures up to 25kgs in the reactor while manufacturing various products in our plant. Capable to perform High vacuum distillation at vacuum levels of 0
Slide 23: Board of Directors
Board of Directors Brief profile of the Board members are available on the website of the Company.
Slide 24: Awards / Accolades
Awards /Accolades 2018 2020 Received the “Outstanding Export Performance Award 2018-19” in “All round-Rising Star” Category from The Received “Pharma Bulk Drug Company of the year ” Pharmaceuticals Export Promotion Council of India. from Govt. of India
Slide 25: Relationships with Marquee Clients
Relationships with Marquee Clients
Slide 26: Company Share Transfer Agents
Company SMS Lifesciences India Limited CIN: L74930TG2006PLC050223 Mr. Trupti Ranjan Mohanty, Compliance Officer : cs@smslife.in | : www.smslife.in Share Transfer Agents M/s. Aarthi Consultants Private Limited Mr. Jagan Mohan Gobburi, Compliance Officer 1-2-285, Domalguda, Hyderabad-500 029, Telan
SMS Lifesciences India — Q4 FY25 Earnings Presentation on 6ix